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Abstract. The identification of biomarkers in urine or serum 
samples from patients with bladder cancer is urgently required 
for the development of non‑invasive methods for the diagnosis 
of bladder carcinoma and to facilitate follow‑up surveillance, 
to combat the high progression and recurrence rates of this 
type of cancer. The current study measured the content of 
matrix metalloproteinase (MMP)‑2 and -9, as well as tissue 
inhibitor of metalloproteinase (TIMP)‑1 and -2 in the urine 
and sera of 41 patients with bladder cancer by ELISA. The 
association between levels of MMP‑2 and ‑9 and TIMP‑1 
and ‑2, and tumor grade and stage were investigated to verify 
whether these molecules are involved in tumor differentiation. 
Statistical analysis of the data revealed that urinary TIMP‑1 
levels were significantly higher in the high grade group 
compared with those of the low grade samples (P=0.022). 
The results also revealed a significantly differing distribution 
of TIMP-1 expression between Ta and T1 stage specimens 
(P=0.040). The corresponding area under the curves (AUCs) 
were 0.72, with a sensitivity of 0.70 and specificity of 0.75. In 
addition, neutrophil gelatinase‑associated lipocalin (NGAL) 
and MMP‑9/NGAL complex levels in the sera were measured. 
All molecules evaluated were detected in the sera of the 
patients studied. In particular, tumors staged as non-muscle 
invasive (Ta and T1), demonstrated significantly higher NGAL 
levels compared with those of muscle invasive (>T1) bladder 
cancer (32.8 ng/ml vs. 16.2 ng/ml; P=0.029). The discrimina-
tory ability of NGAL expression was confirmed by receiver 
operating characteristic curve analysis that revealed an AUC 
of 0.75, a sensitivity of 0.88 and a specificity of 0.67. These 
data indicated that urinary TIMP‑1 and serum NGAL may be 
useful non‑invasive biomarkers to provide clinical information 
for bladder cancer disease management. Multicenter, prospec-
tive studies are required to confirm these preliminary results.
Introduction
Bladder cancer (BCa) is one of the most common urologic 
malignancies worldwide; with a higher frequency amongst 
males than females (1). The two major environmental risk 
factors for BCa are high exposure to tobacco smoke, and 
occupational exposure to aromatic amines, polycyclic 
aromatic hydrocarbons and chlorinated hydrocarbons (2,3). 
Furthermore, exposure to ionizing radiation, a variety of 
lifestyle choices, occupations, dietary factors, drugs, urologic 
pathologies, family history and genetic polymorphisms may 
increase the risk of bladder carcinoma (1‑3). There are two 
clinical phenotypes of bladder carcinoma: Non‑invasive 
and invasive BCa. Non‑invasive BCa includes the papillary 
carcinoma phenotype (Ta) and flat carcinoma in situ (cis). Ta 
bladder carcinoma is superficial and rarely invades the base-
ment membrane or metastasizes, but is associated with a high 
risk of local recurrence; while invasive bladder carcinoma has 
a high risk of disease progression, including muscle invasion 
and metastasis, and mortality. Ta tumorigenesis typically 
occurs via a molecular pathway that is distinct from that of cis 
and the invasive cancer phenotype (4). Superficial tumors are 
generally treated with transurethral tumor resection and intra-
vesical Bacille Calmette‑Guérin, whereas invasive tumors are 
aggressively resected (5). To date, cystoscopy remains the gold 
standard for the diagnosis of malignancies of the bladder. In 
addition, examination by cystoscopy is required not only for 
diagnosis, but also for follow-up. Cytoscopic examination is 
repeated at 3‑month intervals as no other method currently 
available is sufficiently sensitive and specific. However, 
cystoscopy is an invasive, relatively costly and uncomfortable 
diagnostic method, which may also be inconclusive, particu-
larly in the diagnosis of cystitis. Therefore, the development 
of non‑invasive methods for the diagnosis of bladder carci-
noma is urgently required. Urinary or circulating biomarkers 
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represent a potential area of interest for the early detection 
and surveillance of bladder carcinoma due to the high acces-
sibility of samples. Multiple tumor biomarkers have been 
investigated in this capacity, with variable results (6‑9).
An essential change that occurs in malignancies is tissue 
invasion; however, the extracellular matrix (ECM) provides 
a significant barrier to tumor cell invasion. A unique class 
of matrix degrading enzymes, the matrix‑metalloproteinases 
(MMPs), are able to degrade certain components of the 
ECM and basement membrane, facilitating tumor cell 
dissemination. In addition, MMPs have key functions in the 
maintenance of a supportive local environment that promotes 
tumor cell growth at the primary and metastatic sites. The 
ability to degrade type IV collagen, the major component of 
the basement membrane, is unique to MMP‑2 and ‑9. These 
MMPs are frequently associated with the malignant pheno-
type of tumor cells, and their expression has been found 
to be elevated in several cases of human tumors exhibiting 
aggressive characteristics and low overall survival (10,11). As 
a result of their potential and destructive nature, the activities 
of the MMPs are highly regulated at various levels, including 
via transcriptional control, secretion from cells as inactive 
precursors and functional inhibition by the tissue inhibitor 
of metalloproteinases (TIMPs), of which there are four: 
TIMP‑1, TIMP‑2, TIMP‑3 and TIMP‑4 (12). TIMP‑1 binds 
and inhibits MMPs with 1:1 stoichiometry, binding MMP‑9 
in particular; while TIMP‑2 inactivates MMP‑2 specifically. 
Dysregulation of the balance between MMP and TIMP 
expression has been suggested to facilitate tumor progression 
and recurrence in cancer.
A previous study by our group revealed, by gelatin zymog-
raphy, that urinary MMP‑2 and ‑9 expression was correlated 
with increased MMP‑9 lytic activity in high‑grade and 
advanced‑stage bladder cancer (13). In addition, a complex of 
MMP‑9 and human neutrophil gelatinase‑associated lipocalin 
(NGAL) has been detected in the urine of patients with prostate 
cancer and BCa (14). NGAL is an acute-phase protein involved 
in innate immunity, with a crucial role in intracellular iron 
transport (15). NGAL expression is altered in several benign 
conditions, including inflammatory, ischemic and metabolic 
disorders. Furthermore, NGAL is overexpressed in numerous 
types of tumor (15,16), and its expression is associated with 
invasive cancer progression (17,18).
In the present study, urinary and serum levels of MMP‑2, 
MMP‑9, TIMP‑1 and TIMP‑2, as well as serum concentra-
tions of NGAL and MMP‑9/NGAL complex were evaluated 
in samples from 41 patients with bladder carcinoma. These 
levels were compared with tumor grade and stage in order 
to verify whether these molecules may offer potential as 
non‑invasive biomarkers to provide useful clinical informa-
tion for bladder cancer disease management.
Patients and methods
Patients. A total of 41 patients were enrolled at the Departm-
tent of Urology, University of Naples (Naples, Italy) between 
May 2010 and 2011. Samples of first morning urine and 
peripheral venous blood were collected prior to surgical or 
other therapeutic interventions. Standard clinical laboratory 
criteria and histopathological investigations were used to 
diagnose and confirm the tumor type of each patient. Patient 
ages ranged from 40 to 86 years (mean, 71.1±9.3 years; median, 
72 years), and in total, there were 4 females and 37 males. 
The tumors were classified by grade and stage according to 
pTNM classifications (19). All patients included provided 
written informed consent and the study was approved by the 
ethics committee of the University of Naples. A total of 40 
age‑matched, normal, healthy laboratory volunteers were 
recruited as controls and provided their permission verbally. 
Healthy volunteers exhibited no sign of illness and their basic 
laboratory parameter values were confirmed to be within 
reference limits.
Urine sample preparation. The MultistixCombur test 
(Roche Diagnostics GmbH, Mannheim, Germany) was used 
to examine urine samples prior to analysis, and any urine 
samples that tested positive for leukocytes were excluded 
due to the presence of confounding leukocyte gelatinases. 
Microscopic hematuria, which was present in the majority of 
cancer samples, was not quantified; however, samples exhib-
iting macroscopic hematuria were excluded. The samples 
were frozen immediately following collection, and stored at 
‑20˚C prior to analysis. For further analysis, samples were 
thawed and 15‑ml aliquots of each sample were centrifuged 
at 1,000 x g for 10 min at 4˚C. The supernatant was collected 
and the levels of MMP‑2, MMP‑9, TIMP‑1 and TIMP‑2 were 
determined by immunoassay.
Serum. Peripheral venous blood samples were collected in 
vacutainers and allowed to clot for 30 min at room tempera-
ture, prior to centrifugation at 1,600 x g for 10 min at 4˚C. 
The samples were then divided into aliquots and stored at 
‑20˚C prior to the determination of MMP‑2, MMP‑9, TIMP‑1, 
TIMP‑2, NGAL and MMP‑9/NGAL complex levels by immu-
noassay. Each aliquot was used only once, in order to prevent 
enzyme activation due to the freeze‑thawing processes.
Measurement of MMP‑2, MMP‑9, TIMP‑1, TIMP‑2, NGAL 
and MMP‑9/NGAL levels. MMP‑2 and -9, as well as TIMP‑1 
and -2 levels were detected by ELISA using commercial kits 
(Biotrak Cell Proliferation ELISA System) obtained from GE 
Healthcare Life Sciences (Chalfont, UK). These assays were 
based on a two‑site sandwich format, utilizing two antibodies 
directed against various epitopes of each molecule. The 
assay for MMP‑2 detected pro‑MMP‑2 (free pro‑MMP‑2 and 
pro‑MMP‑2 complexed with TIMP‑2), but not the active form 
of MMP‑2. The assay for MMP‑9 recognized pro‑MMP‑9 
(free pro‑MMP‑9 and pro‑MMP‑9 complexed with TIMP‑1). 
The assay for TIMP‑1 detected free TIMP‑1 and TIMP‑1 
complexed with MMP‑9. The assay for TIMP‑2 detected 
free TIMP‑2 and TIMP‑2 complexed with MMP‑2. NGAL 
and MMP‑9/NGAL complex levels were determined with a 
solid-phase immunoassay, using a commercial kit (Quanti-
kine) from R&D Systems (Minneapolis, MN, USA). The 
NGAL assay used two monoclonal antibodies specific for two 
epitopes of lipocalin 2. The MMP‑9/NGAL complex assay 
used monoclonal antibodies against recombinant human 
NGAL, and was therefore unable to detect recombinant 
human MMP‑9 or NGAL in their free forms. All assays were 
conducted according to the manufacturer's instructions.
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Statistical analysis. Descriptive statistics are provided as the 
mean ± standard deviation, or as the median [range] in the case of 
quantitative variables; and as frequencies (percentage) in the case 
of qualitative variables. Student's t-test and the Mann‑Whitney 
U test were used for comparisons of numeric variables between 
groups. Prognostic validity of the various biomarkers was 
evaluated by receiver operating curve (ROC) curve analysis. The 
diagnostic accuracy was measured using the area under the ROC 
curve (AUC) and the corresponding 95% confidence interval (CI).
For all analyses, two‑sided tests were used, and P<0.05 was 
considered to indicate a statistically significant difference.
All statistical analyses were performed using statistical 
computing environment R software (version 3.01; R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
During a 1‑year period, urine and serum samples from a total 
of 41 patients with bladder cancer were evaluated, and the 
histopathological characteristics are listed in Table I.
Table I. Clinical characteristic of 41 patients.
Characteristic Patients, n (%)
Histological grade
  Low grade (G1) 17 (41.5)
  High grade (G3) 24 (58.5)
Tumor stage
  Ta 13 (32.0)
  T1 20 (49.0)
  T2 or higher   8 (19.0)
Gender
  Female   4 (10.0)
  Male 37 (90.0)
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Figure 1. ROC analysis of urinary tissue inhibitor of metalloproteinase‑1 
expression in discriminating between low‑ and high‑grade bladder cancer. 
AUC, area under ROC curve; CI, confidence interval; ROC, receiver oper-
ating curve.
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Levels of MMP‑2 and ‑9, as well as their inhibitors 
TIMP‑1 and ‑2 were determined in urine samples from 
patients and normal controls. The four molecules were 
undetectable in the urine samples from all normal controls. 
By contrast, MMP‑2 and ‑9 were detected in urine samples 
from 26 of 41 (63%) and 25 of 41 (61%) patients with BCa, 
respectively. In patients with detectable MMP‑2 and ‑9, the 
median urinary MMP‑2 concentration was 1.27 ng/ml, and 
the median urinary MMP‑9 concentration was 1.30 ng/ml. 
By contrast, TIMP‑1 and TIMP‑2 were detectable in the 
majority of urine samples from patients with BCa analyzed 
(95 and 83%, respectively), and the median values were 5.48 
and 3.13 ng/ml, respectively. The specimens were divided 
into histological groups according to grade, low grade (G1) 
and high grade (G3); and according to T category, Ta, T1 and 
T2 or higher (Tables II and III).
Figure 3. ROC receiver operating curve analysis for serum neutrophil gela-
tinase‑associated lipocalin in discriminating between non‑muscle invasive 
(stage Ta or T1) and muscle invasive (stage ≥T2) bladder cancer. AUC, area 
under ROC curve; CI, confidence interval; receiver operating curve.
Figure 2. ROC analysis for urinary tissue inhibitor of metalloproteinase‑1 
in discriminating between Ta and T1 stage bladder cancer. AUC, area under 
ROC curve; CI, confidence interval; ROC, receiver operating curve.
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As shown in Table II, urinary TIMP‑1 values were signifi-
cantly higher in the G3 group than those of the low‑grade 
specimens (7.41 [0.6‑139] ng/ml vs. 1.77 [0.2‑46.5] ng/ml; 
P=0.022). The corresponding AUC was 0.72 (95% CI, 0.54‑0.89), 
with a sensitivity of 0.70 and a specificity of 0.75 at a cut‑off 
value of 4.95 ng/ml (Fig. 1). Furthermore, TIMP‑1 also 
demonstrated significantly different expression between 
Ta and T1 stage specimens (1.26 [0.3‑13.1] ng/ml vs. 
6.92 [0.2‑139] ng/ml; P=0.040). The corresponding AUC was 
0.72 (95% CI, 0.55-0.90) with a sensitivity and specificity of 
0.70 and 0.75 at a cut‑off value of 4.95 ng/ml, respectively 
(Fig. 2). Conversely, no significant difference was identified in 
urinary TIMP‑2 concentration between low- and high-grade 
specimens, or among various tumor stages.
The expression of MMP-2 and -9, their inhibitors TIMP-1 
and -2, NGAL and the MMP‑9/NGAL complex were deter-
mined in sera samples. These six molecules were detected in 
the sera of all patients studied. In particular, tumors staged as 
non-muscle invasive (Ta and T1) exhibited significantly higher 
NGAL levels compared with those of muscle invasive BCa 
(32.8 [7.2‑126] ng/ml vs. 16.2 [11.2‑39] ng/ml; P=0.029). The 
discriminatory ability of NGAL expression was confirmed by 
ROC curve analysis that revealed an AUC of 0.75, (95% CI, 
0.60-0.90) and a sensitivity and specificity of 0.88 and 0.67 at 
a cut‑off value of ≤26.1 ng/ml, respectively (Fig. 3).
Discussion
In BCa, the recurrence of treated tumors and the progression 
of tumors to a higher stage and grade represents a significant 
risk. Tumor stage and histological grade are strong prognostic 
factors and provide information useful for the selection of 
appropriate therapeutic modalities. However, clinical staging 
is currently imperfect, resulting in significant discrepancies 
between clinical and pathological stage (20). A potential 
strategy for the improvement of this limitation is the iden-
tification of biomarkers in urine or serum samples, whose 
levels are indicative of tumor forms and are able to be used 
to monitor disease progression. The current study aimed to 
detect biomarkers in the urine and serum of patients with 
bladder cancer, to differentiate between low- and high-grade 
tumors and/or among T stages. MMPs and their inhibitors 
have frequently been investigated in human bladder tissues, 
and their elevated expression in BCa tissue at the messenger 
RNA (mRNA) and protein levels have previously been associ-
ated with advanced tumor stage, grade and decreased survival 
rate (21). Studies have reported that TIMP‑1 is a multifunc-
tional protein with a variety of functions independent of MMP 
inhibition (22). In particular, it has been demonstrated that 
TIMP‑1 is able to stimulate growth in a wide range of cell 
lines, including fibroblasts and epithelial cells, and is corre-
lated with tumor cell proliferation and angiogenesis (23). By 
immunohistochemical analysis, Miyata et al (24) revealed that 
TIMP‑1 expression was associated with high T stage and poor 
prognosis in transitional cell carcinoma of the upper urinary 
tract. The results of the present study demonstrated that 
urinary TIMP‑1 values were able to differentiate between 
low‑ and high‑grade BCa, and between Ta and T1 stage. To 
the best of our knowledge, there are currently few publica-
tions available regarding the detection of TIMP‑1 in urine 
for BCa diagnosis, and these have reported variable results. 
In particular, Durkan et al (25) found that urinary TIMP‑1 
values were significantly higher in patients with cancer than 
those of normal volunteers, with higher values in samples 
from patients with T2‑T4 tumors than those of patients with 
cis Ta/T1 tumors; but identified no significant variation in 
expression with tumor grade. By contrast, Monier et al (26) 
reported that the median value of urinary TIMP‑1 was 
significantly lower in T1‑T4 stage patients than that observed 
in Ta stage specimens.
Furthermore, the present study identified an association 
between NGAL serum levels and BCa stage. Muscle‑invasive 
BCa (>T1) was able to be differentiated from non‑muscle 
invasive BCa (≤T1). Until now, NGAL has been investigated 
primarily as an inflammatory factor and marker of kidney 
damage (15). However, recent studies have indicated that 
NGAL has potential role in cancer development and that 
it may have pro‑oncogenic or anti‑oncogenic functions. In 
particular, it has been reported that the NGAL mRNA tran-
script and protein levels were higher in bladder cancer tissues 
than those in their normal counterparts (27). Accordingly, 
50.5% of cases displayed NGAL transcript levels higher than 
the 75th percentile of the ‘normal’ values, suggesting its role 
as a diagnostic marker (27). These are in agreement with 
the results of previous investigations in which NGAL and 
MMP‑9 were overexpressed in urothelial bladder carcinomas, 
suggesting their role as early diagnostic markers for this tumor 
type (14). Monier et al (26) found reduced protein levels of 
NGAL in urine samples from patients with BCa, suggesting 
that reduced levels of this protein may be used as an indicator 
of tumor progression. To the best of our knowledge there have 
been no previous studies regarding the detection of NGAL in 
the serum of patients with bladder carcinomas. Therefore the 
present association between sera NGAL and bladder tumor 
stage has not previously been reported.
In conclusion, taking these observations together, it was 
suggested that the determination of urinary TIMP‑1 and 
serum NGAL may provide clinicians with additional quanti-
tative and objective information regarding the differentiation 
of bladder tumors. However, due to the small sample size of 
the present study, these conclusions may not be transferable 
to the general population and therefore require further evalu-
ation to validate their diagnostic potential.
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